Few randomized clinical trials support using repository corticotropin injection for most FDA-approved indications, including rheumatoid arthritis, ankylosing spondylitis, lupus, optic neuritis and nephrotic syndrome, according to researchers.
Data published in JAMA Internal Medicine also found that most randomized clinical trials reported that corticotropin (H. P. Acthar Gel, Mallinckrodt Pharmaceuticals) was non-superior to lower-cost corticosteroids for multiple sclerosis and infantile spasms.
“The basic issue here is that repository corticotropin is a very old and very expensive